aTyr Pharma completes last patient visit in Phase 3 EFZO-FIT study.
ByAinvest
Thursday, Aug 7, 2025 4:08 pm ET1min read
ATYR--
The EFZO-FIT™ study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. The study enrolled 268 patients across 85 centers in nine countries and is designed to assess the absolute change in steroid use from baseline to week 48 as the primary endpoint [1].
aTyr Pharma anticipates that the completion of this study represents a significant milestone in its clinical program for efzofitimod in interstitial lung disease (ILD). The company is also advancing efzofitimod in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis (SSc)-related ILD and has advanced ATYR0101 to the investigational new drug (IND) candidate stage for pulmonary fibrosis [1].
The company's financial position remains strong, with cash and investment position at $83.2 million as of June 30, 2025, and an additional $30.7 million raised through an at-the-market (ATM) offering with Jefferies LLC [1]. The company expects its cash runway to be sufficient to fund its operations for a period of one year following the Phase 3 EFZO-FIT™ readout.
aTyr Pharma is focused on leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of ILD, a group of immune-mediated disorders that can cause inflammation and fibrosis of the lungs [1].
References:
[1] https://www.nasdaq.com/press-release/atyr-pharma-announces-second-quarter-2025-results-and-provides-corporate-update-2025
• aTyr Pharma completes last patient visit in Phase 3 EFZO-FIT study. • Topline results expected in mid-September 2025. • Efzofitimod is for pulmonary sarcoidosis treatment. • aTyr Pharma is a clinical stage biotechnology company.
San Diego, CA — aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company, has completed the last patient visit in its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The company expects to report topline results in mid-September 2025 [1].The EFZO-FIT™ study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. The study enrolled 268 patients across 85 centers in nine countries and is designed to assess the absolute change in steroid use from baseline to week 48 as the primary endpoint [1].
aTyr Pharma anticipates that the completion of this study represents a significant milestone in its clinical program for efzofitimod in interstitial lung disease (ILD). The company is also advancing efzofitimod in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis (SSc)-related ILD and has advanced ATYR0101 to the investigational new drug (IND) candidate stage for pulmonary fibrosis [1].
The company's financial position remains strong, with cash and investment position at $83.2 million as of June 30, 2025, and an additional $30.7 million raised through an at-the-market (ATM) offering with Jefferies LLC [1]. The company expects its cash runway to be sufficient to fund its operations for a period of one year following the Phase 3 EFZO-FIT™ readout.
aTyr Pharma is focused on leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of ILD, a group of immune-mediated disorders that can cause inflammation and fibrosis of the lungs [1].
References:
[1] https://www.nasdaq.com/press-release/atyr-pharma-announces-second-quarter-2025-results-and-provides-corporate-update-2025
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet